GlassScriptPhysician profile
Alan R Bank
NPI 1538163464
$14,817.40
in general payments reported to CMS, 2019-2025
46 companies · $3,155 in 2025
The $3,155 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,168 · 2020: $1,288 · 2021: $2,247 · 2022: $1,540 · 2023: $2,565 · 2024: $1,854 · 2025: $3,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,550 · Education: $23.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,549.84 |
| Education | $23.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,249.87 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $1,844.17 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,097.94 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $879.19 | 2021-2023 | Zeposia |
| Celgene Corporation | $581.09 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $505.54 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $497.62 | 2019-2025 | |
| Madrigal Pharmaceuticals | $454.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $441.38 | 2024-2025 | Voquezna |
| Genzyme Corporation | $432.10 | 2023-2025 | |
| Qol Medical, LLC | $412.42 | 2019-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $393.53 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $360.25 | 2019-2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $334.30 | 2020-2023 | |
| Ipsen Biopharmaceuticals, INC | $234.19 | 2025 | Iqirvo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.